CRISPR Therapeutics and Casebia Therapeutics Announce … – GlobeNewswire (press release)
DIGITALLOOK |
CRISPR Therapeutics and Casebia Therapeutics Announce …
GlobeNewswire (press release) CRISPR Therapeutics and Casebia obtain commercial rights to MaxCyte's cell engineering platform to develop CRISPR/Cas9-based therapies. CRISPR Therapeutics Licenses Cell Engineering Platform From MaxCyte CRISPR & Bayer acquire license to cell engineering technology MaxCyte signs cell platform deal with CRISPR and Casebia |
